8-K: Phio Pharmaceuticals Reports Year-End Financial Results and Highlights Clinical Trial Progress

Phio Pharmaceuticals announces its 2024 year-end financial results and provides a business update, emphasizing the progress of its PH-762 clinical trial.

Summary

• Phio Pharmaceuticals reported its financial results for the year ended December 31, 2024, and provided a business update.
• The company is currently evaluating PH-762 in a Phase 1b dose-escalating clinical trial for the treatment of patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
• The third dose cohort is fully enrolled, and the company expects to complete enrollment of all patients in the study in the third quarter of 2025.
• In December 2024 and January 2025, Phio raised approximately $9.2 million in registered direct offerings and concurrent private placements.
• An additional $2.9 million was raised from the exercise of warrants previously issued on July 12, 2024.
• The company believes it has sufficient capital to complete the treatment phase of the Phase 1b trial.
• Phio commenced a cost rationalization program in 2023, resulting in the non-renewal of its building lease in Marlborough, MA, which expired on March 31, 2024.
• The company terminated its Clinical Co-Development Agreement with AgonOx, Inc. in May 2024 to focus on its self-directed phase 1b clinical trial with PH-762.
• Phio's portfolio includes 77 issued patents, 69 of which cover its INTASYL technology.
• The company presented new data on its INTASYL self-delivering siRNA technology at several conferences during 2024.
• At December 31, 2024, the company had cash of approximately $5.4 million, compared to $8.5 million at December 31, 2023.
• Research and development expenses for the year ended December 31, 2024, decreased by approximately $2.7 million, or 42%, compared to the year ended December 31, 2023.
• Net loss was approximately $7.2 million, or ($9.08) per share, for the year ended December 31, 2024, compared to a net loss of approximately $10.8 million, or $46.76 per share, for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. Positive clinical trial results and successful capital raising are offset by a decrease in cash position and ongoing net losses. The cost rationalization efforts are viewed favorably, suggesting a proactive approach to financial management.

Positives

• Two patients in the second dose cohort of the PH-762 trial showed a complete response (100% tumor clearance) at Day 36.
• Phio raised approximately $9.2 million in registered direct offerings and concurrent private placements in December 2024 and January 2025.
• An additional $2.9 million was raised from warrant exercises.
• The company believes it has sufficient capital to complete the treatment phase of the Phase 1b trial.
• Research and development expenses decreased by 42% due to cost rationalization measures.
• Net loss decreased from $10.8 million in 2023 to $7.2 million in 2024.

Negatives

• The company's cash position decreased from $8.5 million at the end of 2023 to $5.4 million at the end of 2024.
• The company incurred a net loss of $7.2 million for the year ended December 31, 2024.

Risks

• The company's future performance is subject to risks identified in their Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption 'Risk Factors'.
• The company's actual results may differ materially from those indicated in the forward-looking statements due to a number of important factors, including the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions.

Future Outlook

Phio expects to complete enrollment of all patients in the PH-762 study in the third quarter of 2025 and believes it has sufficient capital to complete the treatment phase of the Phase 1b trial.

Industry Context

Phio Pharmaceuticals is operating in the competitive biotechnology industry, specifically focusing on immuno-oncology therapeutics. The company's INTASYL siRNA technology aims to enhance the ability of immune cells to kill tumor cells, aligning with the broader industry trend of developing targeted immunotherapies for cancer treatment. Companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals are also developing RNAi-based therapeutics, but Phio's self-delivering INTASYL technology differentiates it from others that require formulation enhancements.

Comparison to Industry Standards

• Phio's focus on self-delivering RNAi technology for immuno-oncology places it in a competitive landscape with companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, which are also developing RNAi-based therapeutics.
• Alnylam's Onpattro, an approved RNAi therapeutic, demonstrates the potential of this technology, but it targets a different disease area (hereditary transthyretin-mediated amyloidosis).
• Arrowhead Pharmaceuticals is developing RNAi therapies for various indications, including liver diseases and cancer, using its TRiM platform.
• Phio's Phase 1b trial results showing complete tumor clearance in some patients are promising, but further clinical trials are needed to confirm these findings and compare them to existing cancer therapies.
• The company's cost rationalization efforts and focus on product development are consistent with industry trends for smaller biotech companies to prioritize key programs and manage expenses.

Stakeholder Impact

• Shareholders: The clinical trial progress and capital raising activities could positively impact shareholder value.
• Employees: Cost rationalization measures and headcount reductions may have impacted employees.
• Patients: The development of PH-762 could provide a new treatment option for patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Next Steps

• Complete enrollment of all patients in the PH-762 study in the third quarter of 2025.
• Continue evaluating PH-762 in the Phase 1b dose-escalating clinical trial.
• Advance the INTASYL siRNA gene silencing technology to eliminate cancer.

Key Dates

Keywords

PH-762, INTASYL, siRNA, clinical trial, immuno-oncology, gene silencing, biotechnology, pharmaceuticals, cancer therapy